These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9352395)

  • 1. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics--observations with beta-adrenoceptor antagonists.
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):453-7. PubMed ID: 9352395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
    de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
    Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
    van Steeg TJ; Freijer J; Danhof M; de Lange EC
    Br J Pharmacol; 2007 Jun; 151(3):356-66. PubMed ID: 17420778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.
    Höcht C; Bertera FM; Del Mauro JS; Taira CA
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):525-41. PubMed ID: 24593316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
    Sica DA
    Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
    Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled-release carvedilol: a concluding perspective.
    Packer M
    Am J Cardiol; 2006 Oct; 98(7A):67L-69L. PubMed ID: 17023235
    [No Abstract]   [Full Text] [Related]  

  • 10. Does the beta 1-adrenoceptor blocking agent celiprolol have alpha 2-adrenoceptor blocking properties?
    Pittner H
    Arch Int Pharmacodyn Ther; 1987 Feb; 285(2):199-210. PubMed ID: 2883946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach.
    van Steeg TJ; Boralli VB; Krekels EH; Slijkerman P; Freijer J; Danhof M; de Lange EC
    J Pharm Sci; 2009 Oct; 98(10):3816-28. PubMed ID: 19117045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
    Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
    Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
    Wellstein A; Palm D; Belz GG; Butzer R; Polsak R; Pett B
    Eur Heart J; 1987 Dec; 8 Suppl M():3-8. PubMed ID: 2897299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of minimal cardiac transit times in normal persons during beta-sympathicolysis (author's transl)].
    Freundlieb C; Höck A; Vyska K; Smolarz A; Feinendegen LE
    Nuklearmedizin; 1979; 18(6):274-7. PubMed ID: 43966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.
    Vinceneux P; Canal M; Domart Y; Roux A; Cascio B; Orofiamma B; Larribaud J; Flouvat B; Carbon C
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):153-8. PubMed ID: 2870990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
    Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR
    J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the activity of beta-adrenoceptor antagonists in man.
    Taylor SH; Thadani U; Davidson C; singleton W; Myint S
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):305-6. PubMed ID: 240783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent.
    Miyagishi A; Nakahara H; Hara Y
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):249-62. PubMed ID: 6210068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative potency of intravenous penbutolol and propranolol in man.
    Sharma PL; Sapru RP
    Int J Clin Pharmacol Biopharm; 1978 Feb; 16(2):83-5. PubMed ID: 24597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
    Qvigstad E; Sjaastad I; Bøkenes J; Schiander I; Solberg L; Sejersted OM; Osnes JB; Skomedal T
    Eur J Pharmacol; 2005 May; 516(1):51-9. PubMed ID: 15916756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.